Repurposing Melatonin Receptor Agonists as Adjunct Treatments for Smoking Cessation
重新利用褪黑激素受体激动剂作为戒烟的辅助治疗
基本信息
- 批准号:9144346
- 负责人:
- 金额:$ 23.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-15 至 2018-08-31
- 项目状态:已结题
- 来源:
- 关键词:AbstinenceAddressAgonistAttenuatedCarbon MonoxideClinical TrialsConstipationCoupledCrossover DesignDataDevelopmentFDA approvedFemaleFoundationsFutureHeadacheHealthHumanIncentivesIndividualIndividual DifferencesInterventionLaboratoriesLeadMarketingMeasuresMelatonin ReceptorsMental DepressionModelingMoodsNicotine DependenceNicotine WithdrawalOutcomePatient Self-ReportPharmaceutical PreparationsPharmacological TreatmentPharmacotherapyPhasePhysical DependencePlacebo ControlPlacebosPopulationProceduresPropertyRebound InsomniaRecording of previous eventsRelapseResearchResearch DesignResidual stateRiskSafetySamplingSignal TransductionSleepSleep DisordersSleep disturbancesSleeplessnessSmokerSmokingStagingStudy SubjectSymptomsTestingTherapeuticWithdrawalWithdrawal SymptomWithholding Treatmentbasecritical perioddiariesdrug developmentexperiencefallsgender differenceimprovedindexinginnovationnegative moodnicotine patchnicotine replacementnovelnovel strategiesprimary outcomescreeningsleep onsetsmoking cessationsmoking relapsesuccesstherapeutic targettreatment effectvarenicline
项目摘要
DESCRIPTION (provided by applicant): Even with the use of FDA-approved pharmacotherapies for smoking cessation, most smokers relapse within the first few days following a quit attempt. Thus, there is a need to identify novel approaches to optimize treatment to help more smokers maintain abstinence during this critical period. Evidence indicates that sleep disturbance during nicotine withdrawal may be an important, yet overlooked smoking cessation treatment target. This is particularly important since existing treatments do not mitigate withdrawal-related sleep disturbance. Critically, difficulty sleeping is predictive of smoking relapse. In this proof-of-concept study, we hypothesize that the FDA-approved melatonin receptor agonist, ramelteon, in combination with transdermal nicotine replacement therapy (TN), will promote smoking cessation by attenuating sleep disturbance during nicotine withdrawal. Using a well-validated medication screening paradigm, we propose a within-subject, placebo-controlled crossover design with one within-subjects factor of short-term medication (ramelteon vs. placebo). Fifty treatment-seeking smokers will complete this 6-week study, which consists of two 2-week phases separated by a 2-week washout. Each phase includes 1 week of ad libitum smoking (baseline) and 1 week of medication (8mg ramelteon or placebo) plus TN while trying to abstain (quit assessment). Smokers will be provided small monetary incentives for biochemically-confirmed abstinence. Ramelteon's unique properties reduce the likelihood of next-day residual effects, rebound insomnia, and symptoms of physical dependence which render other sleep medications problematic. We have chosen TN because it will be important to address physical nicotine withdrawal symptoms (e.g., headaches, constipation) and it is the most widely used treatment in the U.S. For the duration of the study, subjects will be asked to keep sleep diaries and wear an armband while sleeping which provides objective indices of sleep duration and quality (SensewearPro). All subjects will receive standard TN following completion of the study. The primary outcome will be the total number of days abstinent (out of five), confirmed by carbon monoxide breath sample. This measure is highly predictive of longer-term quit success. Intermediate outcomes will include sleep onset latency (self-report) and sleep efficiency (SensewearPro armband). This innovative line of research will be the first to repurpose a melatonin receptor agonist (ramelteon) to evaluate its effects on withdrawal-related sleep disturbance and short-term quitting success in treatment-seeking smokers. Repurposing medications that have been "de-risked" removes a key barrier to drug development (i.e., safety signals), increasing the likelihood that the drug will be brought to market. Critically, our study design permits exploration of putative mechanisms that underlie the treatment effect. If our hypotheses are supported, these data will lay the foundation for a larger Stage II clinical trial and to extend this adjunct pharmacological treatment to other treatments for smoking cessation.
描述(由申请人提供):即使使用FDA批准的药物戒烟,大多数吸烟者在戒烟尝试后的头几天内复发。因此,有必要确定新的方法来优化治疗,以帮助更多的吸烟者在这一关键时期保持戒烟。有证据表明,尼古丁戒断期间的睡眠障碍可能是一个重要但被忽视的戒烟治疗目标。这一点尤其重要,因为现有的治疗方法不能减轻戒断相关的睡眠障碍。重要的是,睡眠困难是吸烟复发的预测。在这项概念验证研究中,我们假设FDA批准的褪黑激素受体激动剂雷美替酮与经皮尼古丁替代疗法(TN)联合使用,将通过减轻尼古丁戒断期间的睡眠障碍来促进戒烟。使用经过充分验证的药物筛选范例,我们提出了一个受试者内安慰剂对照交叉设计,其中一个受试者内因素为短期药物(雷美替翁与安慰剂)。50名寻求治疗的吸烟者将完成这项为期6周的研究,该研究包括两个为期2周的阶段,中间间隔2周的洗脱期。每个阶段包括1周的自由吸烟(基线)和1周的药物治疗(8 mg雷美替酮或安慰剂)加TN,同时尝试戒烟(戒烟评估)。吸烟者将获得少量的金钱奖励,以鼓励他们在生化方面证实戒烟。Ramelteon的独特性质降低了第二天残留效应,反弹失眠和身体依赖症状的可能性,这些症状使其他睡眠药物成为问题。我们选择TN是因为它对解决身体尼古丁戒断症状(例如,在研究期间,受试者将被要求保持睡眠日记并在睡眠时佩戴臂章,这提供了睡眠持续时间和质量的客观指标(SensewearPro)。所有受试者将在研究完成后接受标准TN。主要结果是通过一氧化碳呼气样本确认的禁欲总天数(五天)。这一指标高度预测了长期戒烟的成功率。中间结果将包括睡眠开始潜伏期(自我报告)和睡眠效率(SensewearPro臂章)。这项创新的研究将是第一个重新利用褪黑激素受体激动剂(雷美替酮)来评估其对寻求治疗的吸烟者的戒断相关睡眠障碍和短期戒烟成功的影响。重新使用已经“去风险”的药物消除了药物开发的一个关键障碍(即,安全性信号),增加药物上市的可能性。重要的是,我们的研究设计允许探索治疗效果的潜在机制。如果我们的假设得到支持,这些数据将为更大规模的II期临床试验奠定基础,并将这种辅助药物治疗扩展到其他戒烟治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rebecca Ashare其他文献
Rebecca Ashare的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rebecca Ashare', 18)}}的其他基金
Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort study
评估接受癌症免疫治疗的患者使用大麻的益处和危害:一项前瞻性队列研究
- 批准号:
10792109 - 财政年份:2023
- 资助金额:
$ 23.76万 - 项目类别:
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study
门诊癌症患者的大麻使用和结果:一项为期 12 个月的队列研究
- 批准号:
10818686 - 财政年份:2022
- 资助金额:
$ 23.76万 - 项目类别:
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study
门诊癌症患者的大麻使用和结果:一项为期 12 个月的队列研究
- 批准号:
10610465 - 财政年份:2022
- 资助金额:
$ 23.76万 - 项目类别:
Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers
HIV 吸烟者尼古丁代谢比率的决定因素和结果
- 批准号:
10330407 - 财政年份:2020
- 资助金额:
$ 23.76万 - 项目类别:
Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers
HIV 吸烟者尼古丁代谢比率的决定因素和结果
- 批准号:
10573496 - 财政年份:2020
- 资助金额:
$ 23.76万 - 项目类别:
Determinants and Outcomes of Nicotine Metabolite Ratio in HIV + Smokers
HIV 吸烟者尼古丁代谢比率的决定因素和结果
- 批准号:
9927113 - 财政年份:2020
- 资助金额:
$ 23.76万 - 项目类别:
Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction
针对 HIV 相关炎症和认知功能障碍的胆碱能通路
- 批准号:
10201539 - 财政年份:2017
- 资助金额:
$ 23.76万 - 项目类别:
Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction
针对 HIV 相关炎症和认知功能障碍的胆碱能通路
- 批准号:
9413656 - 财政年份:2017
- 资助金额:
$ 23.76万 - 项目类别:
Repurposing Melatonin Receptor Agonists as Adjunct Treatments for Smoking Cessation
重新利用褪黑激素受体激动剂作为戒烟的辅助治疗
- 批准号:
9014081 - 财政年份:2015
- 资助金额:
$ 23.76万 - 项目类别:
Repurposing cholinesterase inhibitors for smoking cessation
重新利用胆碱酯酶抑制剂来戒烟
- 批准号:
9233957 - 财政年份:2013
- 资助金额:
$ 23.76万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 23.76万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 23.76万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 23.76万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 23.76万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 23.76万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 23.76万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 23.76万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 23.76万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 23.76万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 23.76万 - 项目类别:
Research Grant